Categories: News

Cronos Group Inc. Announces Results of 2023 Annual Meeting of Shareholders

TORONTO, June 23, 2023 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announces that at its Annual Meeting of Shareholders held yesterday, June 22, 2023 (the “Meeting”), shareholders holding a total of 247,410,987 common shares of the Company voted in person or by proxy, representing 64.96% of the total number of common shares of the Company outstanding.

Each of the directors listed as a nominee in the Company’s proxy statement dated April 28, 2023 (the “Proxy Statement”) was elected as a director of the Company, with each director receiving in excess of 94.8% of the votes cast in favor of his or her election. The detailed results of the vote for the election of directors are as follows:

Name of Director Number of Shares
Voted For
Percentage of Shares
Voted For
Number of Shares
Withheld from Voting
Percentage of Shares
Withheld from Voting
Jason Adler 190,713,661 95.83% 8,290,842 4.16%
Kendrick Ashton, Jr. 191,326,512 96.14% 7,677,991 3.85%
Kamran Khan 188,677,722 94.81% 10,326,781 5.18%
Dominik Meier 188,699,733 94.82% 10,304,770 5.17%
Michael Gorenstein 192,713,928 96.83% 6,290,575 3.16%
Elizabeth Seegar 188,789,168 94.86% 10,215,335 5.13%
James Rudyk 190,066,982 95.50% 8,937,521 4.49%

Shareholders also approved an advisory (non-binding) resolution on the compensation of the Company’s named executive officers, with 92.71% of votes cast in favor of such resolution, and approved the re-appointment of KPMG LLP as the Company’s independent auditors.

For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company’s SEDAR profile at www.sedar.com and the Company’s Form 8-K filed on EDGAR at www.sec.gov/edgar.

About Cronos
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.

Forward-looking Statements
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about Cronos’ intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and quarterly report on Form 10-Q for the quarter ended March 31, 2023, which have been filed on SEDAR and EDGAR and can be accessed at www.sedar.com and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

Cronos Contact
Shayne Laidlaw
Tel: (416) 504-0004
investor.relations@thecronosgroup.com

Staff

Recent Posts

NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…

7 hours ago

MyndTec Inc. Completes Ninth Tranche of Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - December 12, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"),…

9 hours ago

Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) is pleased to announce…

9 hours ago

ISHI Health Launches Virtual Heart Failure Clinics in California and Arizona

SAN DIEGO, Dec. 12, 2025 /PRNewswire/ -- ISHI Health, an innovator in AI-enabled virtual cardiac…

9 hours ago

Zealthy Review 2026: How Zealthy Compares to FitRx and RoenRx for Weight Loss & GLP-1 Care

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight…

9 hours ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP)…

9 hours ago